Carriers of PGVs in BRCA1 and BRCA2 are highly susceptible to CBC development with a risk of 2.5% per year after diagnosis of the first BC [24], which is at least five times higher than in non-carriers [2,3]. This evidence concerns the gene BRCA2 and breast cancer.